misleading statements

Coty faces class action lawsuit after 70% profit decline, CEO departure, and withdrawn guidance contradicted November investor assurances.

Law firm files class action against Concorde International Group alleging false statements, social media manipulation, insider share dumping, and artificial trading activity.

Class action alleges Eos Energy ($EOSE) executives hid production capacity issues, manufacturing delays, and quality control problems from investors between November 2025 and February 2026.

Rosen Law Firm urges Nektar investors to join securities class action alleging false statements about REZOLVE-AA trial enrollment. Deadline: May 5, 2026.

Rosen Law Firm filed securities class action against Trip.com over alleged false statements on regulatory risks. Investors have until May 11, 2026 to become lead plaintiffs.

Lawsuit filed against $CORT alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects, concealing regulatory concerns.

Hercules Capital faces class action lawsuit alleging CEO and CFO certified misleading statements on valuations. Stock fell 7.9% February 27.

$FBRT faces securities fraud lawsuit after disclosing over-distributed capital and earnings declines, triggering 14.2% stock drop. Shareholders must file by April 27, 2026.

Boston Scientific faces securities fraud lawsuit over undisclosed EP segment weakness, triggering 17.6% stock decline and May 4 lead plaintiff deadline.

Law Offices of Howard G. Smith seeks lead plaintiffs in securities fraud cases against $CHOW, $GO, $ALIT, $IT before mid-May 2026 deadline.

Class action lawsuit filed against Gossamer Bio alleging material misstatements regarding Phase 3 PROSERA study results and hidden design flaws at Latin American test sites.

Class action lawsuit filed against $CIGL alleging false statements, social media fraud, and insider share dumping between April-July 2025.

PSIX sued for allegedly misleading investors about data center sales prospects and understating manufacturing costs. Class action covers May 2025–March 2026 purchases.

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements about reproxalap clinical trial results, covering investors from November 2023 through March 2026.

Rosen Law Firm recruits lead plaintiffs in class actions against CIGL, FBRT, IBRX over alleged fraud; May 20, 2026 deadline critical.

Rosen Law Firm seeks lead plaintiffs in class action against $VITL over alleged misstatements regarding ERP system delays that caused missed 2025 guidance.

Apollo Global Management faces class action lawsuit over undisclosed Epstein connections. Stock plummeted 15%, erasing $12B in market value following February investigative reports.

Hagens Berman alerts $CORT investors to April 21 lead plaintiff deadline in securities fraud lawsuit over failed relacorilant drug approval and alleged FDA warning concealment.

Rosen Law Firm files securities class action against New Era Energy & Digital ($NUAI) alleging false statements on Texas data centers and fraudulent New Mexico oil well scheme. Lead plaintiff deadline: June 1, 2026.

Rosen Law Firm reminds $ALDX investors of May 29, 2026 deadline to join securities class action alleging false reproxalap trial disclosures.